SM
CRL icon

SG3 Management’s Charles River Laboratories CRL Stock Holding History

SG3 Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,000
Closed -$750K – 1223
2020
Q4 		$750K Buy
3,000
+1,000
+50% +$238K 0.01% 625
2020
Q3 		$453K Buy
+2,000
New +$415K 0.02% 593

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's CRL Position: Q1 2021 in Review

SG3 Management sold out of Charles River Laboratories (CRL) in Q1 2021, closing a stake of 3,000 shares — an estimated $750K sold.

SG3 Management first reported a position in CRL in Q3 2020 and held it in 2 quarters. The position peaked at $750K in Q4 2020. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2021.

  • SG3 Management reported no remaining Charles River Laboratories position as of Q1 2021 after selling out during the quarter.
  • SG3 Management sold 3,000 Charles River Laboratories shares in Q1 2021, an estimated $750K.
  • SG3 Management first reported a position in Charles River Laboratories in Q3 2020 and held it in 2 quarters.
  • SG3 Management's Charles River Laboratories position peaked at $750K in Q4 2020.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.